Author(s)

Junfan Chen, Chongyi Hu, Jie Liu

Corresponding Author

Junfan Chen

ABSTRACT

Tumor mutational burden（TMB）are considered a prerequisite for anti-tumor immunotherapy. A number of clinical studies have used whole-exome sequencing (WES) to explore the value of TMB in clinical applications. But WES is not currently feasible at the scale of a clinical setting. Methods: Following the same analysis done by the original study, the TMB and FGA are examined using the Mann-Whitney U test. For the survival analysis, the standard Kaplan-Meier curves were utilized for the comparison of survival status difference between different factors. Hazard ratios (HRs) for factors were also calculated trough Cox proportional hazards models. Coefficient of determination and related statistical evaluations measures are conducted. Aalen’s Additive Regression Model are also tested for the overtime influence of each factor has over the survival object constructed for the survival analysis. Results: The majority of the patients progress at between 1 months to 5 months and above. The progression of disease would then slow down and having only few patients that reaches 25 months and above. Given the HRs, the middled aged patient with the MSK-IMPACT profiling on panel 410 are comparatively receiving the lowest possible risks in disease progression. Conclusions: In conclusion, while it is verifiable the TMB would heavily impact the NSCLC patient survival, their specific impact relationship are difficult to determine due to the lack of specific data classification, lack of data with solid support, data sensitivity should be improved along with the sample bias problem.

KEYWORDS

TMB, Kaplan-Meier, PFS, NGS, Non-small cell lung cancer